CQDM – Quantum Leap Pharma-led Funding Program for Drug Discovery Research
CQDM’s Quantum Leap pharma-led funding program for drug discovery research helps SMEs or Canadian universities achieve innovative translational biopharmaceutical research projects. Projects selected as part of the Quantum Leap program focus on developing cutting-edge technologies with the potential to significantly advance the R&D activities of CQDM’s pharmaceutical members.
Comments on Funding:
Funding may consist in a grant or an investment.
Requested funds must range from $500,000 to $1,200,000. Exceptionally, CQDM may consider applications exceeding the maximum, if appropriate.
Applicants are responsible for raising matched funding for the project.
- be SMEs and public research institutions in Canada;
- conduct drug discovery research.
The applicant must:
submit a revised application, if required, including any additional information required and addressing comments, concerns and questions issued by the interested pharmaceutical members and/or CQDM’s Scientific Advisory Board.
Applicants must submit the CVs of all involved researchers.
Other Things to Note:
- CQDM is a non-profit biopharmaceutical research consortium whose mission is to support and facilitate multi-stakeholder collaborative R&D that accelerates translation of leading-edge discoveries into vaccines, therapeutics and diagnostics addressing unmet medical needs while generating significant benefits for the Canadian economy.
- Call for proposals are open year-round for Quantum Leap projects. Deadline to participate in the next selection round: November 17th, 2022
When It Ends:
November 17, 2022
Next deadlines to be determined